Steven Joniau graduated in Urology in 2002 at the Catholic University of Leuven. In 2003, he was appointed full-time staff member at the Dept. of Urology, University Hospitals Leuven after a 1-year fellowship at the University Hospital of Wales, Cardiff, UK. In July 2012, he obtained his PhD in Medical Sciences entitled ‘High-risk localized prostate cancer: the role of surgery and the development of clinical outcome prediction models’. In 2013, he was appointed Assistant Professor at the Catholic University of Leuven. His principal field of interest is the management of urological cancers. He is heavily involved in uro- oncological surgery and the multidisciplinary approach of pelvic cancers. He also leads numerous research projects at the University Hospitals Leuven, which focus on lymph node staging in prostate cancer, surgical management and biomarker development of high-risk prostate cancer, the natural history of premalignant lesions of the prostate, chemoprevention of prostate and bladder cancer, minimally invasive treatment of renal cell cancer and prostate cancer, etc. Steven Joniau is scientific secretary of the BVU (Belgische Vereniging voor Urologie), he is past- chairman of the Renal Cell Carcinoma Group of the Young Academic Urologists Working Party of the EAU, he is member of the EAU Guideline Panel on Prostate Cancer and the SIOG Prostate Cancer Guideline Panel. He is also a member of several international scientific societies: EAU, SIU (Société Internationale d’Urologie), SIOG (International Society of Geriatric Oncology) and EORTC GUCG (European Organisation for Research and Treatment of Cancer, Genito-Urinary Cancers Group). He is appointed Associate Editor of ‘The Journal of OncoPathology’. He is Editorial Advisory Board member of ‘The European Journal of Surgical oncology’, Editorial Board member of ‘The Open Prostate Cancer Journal’, ‘Archivo Italiano di Urologia e Andrologia’, ‘The Central European Journal of Urology’ and International Scientific Board member of ‘Archivos Españoles de Urología’. Steven Joniau has received several international awards, of which the First prize of the Urological Challenge Session, received at the 2010 European Urology Forum in Davos, Switzerland, the Crystal Matula Award 2011, received at the 2011 EAU annual congress in Vienna, Austria and the biannual Orion International Oncology Award 2011, received at the 2011 EAU annual congress in Vienna, Austria are the most prestigious. In the last 10 years, he has published >170 papers in peer-reviewed journals in the field of uro- oncology and minimally invasive surgery. He received the Prize for the Best Paper published on Clinical Research in the Urological Literature at the EAU annual congress in Stockholm. He authored several book chapters, he has been invited Faculty in over 85 international congresses and is a faculty member of the ESU (European School of Urology).
GU CONNECT has developed a comprehensive resource which is available on ESMO OncologyPRO, providing information on PARP inhibitors in prostate cancer
Prof. Steven Joniau provides an overview of nmCRPC and highlights of the SPARTAN, PROSPER and ARAMIS trials including the recent overall survival update and discusses the safety and quality of life data.